The study found that low-dose aspirin may improve the survival rate of patients with head and neck cancer and lung cancer

Recently, scientists from Roswell Park Comprehensive Cancer Research Center and other institutions found that low-dose aspirin can improve the survival rate of head and neck cancer and lung cancer patients through two studies In the first study, the researchers reviewed data from 460 head and neck squamous cell carcinoma (HNSCC) or early non-small cell lung cancer (NSCLC) The researchers found that non steroidal anti-inflammatory drugs (http:// such as low-dose aspirin, combined with standard radiotherapy or chemotherapy, could increase the survival rate of these cancer patients by 8% In the second study, the researchers studied 164 NSCLC patients who received precise, high-dose radiotherapy, 57% of whom received aspirin and achieved 2-year survival (compared with 48% of the other patients) Dr Austin Iovoli, the researcher, said these patients will live longer, although anti-inflammatory drugs seem to have little effect on the effectiveness of cancer treatment These studies provide scientists with new ideas and research basis for further research, and also prove the benefits of non steroidal anti-inflammatory drugs (such as aspirin) in the treatment of cancer patients Although clinical trials (http:// are still needed to give a clear suggestion, the researchers encourage patients to communicate with their doctors to use aspirin reasonably so as to improve their anti-cancer treatment.